ATOR-4066
ATOR-4066 is a preclinical first-in-class bispecific antibody developed using Neo-X-Prime™ technology. It binds CD40 and the tumor-associated antigen CEACAM5, with the aim to induce a potent anti-tumor response and remodeling the tumor microenvironment for more effective cancer treatment.
ATOR-4066 is a bispecific antibody developed by Alligator within the Neo-X-Prime™ concept as a sequel to mitazalimab. In addition to CD40, ATOR-4066 targets CEACAM5 (carcino-embryonic antigen 5). CEACAM5 is a protein found in certain tumors, for example colorectal cancer, but not at all or in low amounts in normal tissue, which makes it an attractive target molecule for cancer treatment. Preclinical data show that ATOR-4066 selectively activates dendritic cells and T cells in material form human tumors, and that this activation is dependent on CEA expression in the tumor. Moreover, data from experimental models demonstrate that the molecule activates the immune system and protects against tumors. These results were recently published in the peer-reviewed journal JITC.1
The mechanism and potential of ATOR-4066 was strengthened further during the data published at SITC in November 2024 showing that ATOR-4066 alone can eliminate large tumors with heterogenous CEA-expression, thereby limiting tumor-escape mechanisms and forming the basis for single agent use of the molecule in certain cancers. Based on these positive data, Alligator expects to initiate CMC process development and other IND-enabling activities for ATOR-4066 as soon as possible, dependent on operational and financial capability.
In January 2024, the USPTO granted the first US patent for ATOR-4066.
Project status
1 J Immunother Cancer. 2022 Nov;10(11):e005018. doi: 10.1136/jitc-2022-005018.